ProSomnus Contributes Two Scientific Abstracts Accepted for Presentation at the 2024 American Academy of Dental Sleep Medicine Annual Meeting
May 13, 2024 09:00 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Contributes Two Scientific Abstracts Accepted for Presentation at the 2024 American Academy of Dental Sleep Medicine Annual Meeting
Four Independent Scientific Abstracts at the American Academy of Dental Sleep Medicine Annual Meeting Feature ProSomnus Intraoral Medical Devices
May 09, 2024 18:30 ET
|
ProSomnus Sleep Technologies, Inc.
Four Independent Scientific Abstracts at the American Academy of Dental Sleep Medicine Annual Meeting Feature ProSomnus Intraoral Medical Devices
ProSomnus Sleep Technologies Takes Strategic Action to Position Company for Long-Term Success
May 08, 2024 20:53 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Sleep Technologies Takes Strategic Action to Position Company for Long-Term Success
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
February 22, 2024 08:30 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
January 30, 2024 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
January 29, 2024 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea
January 08, 2024 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, welcomes the adoption of...
Apnimed Announces First Patient Dosed in SynAIRgy, the Second Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
December 21, 2023 08:30 ET
|
Apnimed, Inc.
-- SynAIRgy Compares AD109 to Placebo Over 6 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care -- Part of a two-study...
Apnimed Announces Launch of Joint Venture with Shionogi to Develop Novel Pharmacologic Therapies for Obstructive Sleep Apnea and other Sleep Disorders
October 31, 2023 20:00 ET
|
Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Sleep Apnea Implants Market Worth $803.26 Million by 2030 - Exclusive Report by The Insight Partners
October 18, 2023 08:18 ET
|
The Insight Partners
Pune, India, Oct. 18, 2023 (GLOBE NEWSWIRE) -- North America accounted for the largest share of the global sleep apnea implants market in 2022. The North America sleep apnea implants market has...